FIELD: biotechnology, pharmacology; medicine.
SUBSTANCE: invention relates to methods for preventing allergic inflammation and asthmatic state. Disclosed is an antiallergic agent containing Rhodobacter capsulatus PG lipopolysaccharide (LPS) as an active substance, specifically suppressing activation of immune cells to synthesis and release of pro-inflammatory cytokines TNF-α and IL-8, induced by household dust allergen Dermatophagoides pteronyssinus.
EFFECT: invention allows extending the range of nontoxic antiallergic agents.
1 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR BLOCKING THE EFFECTS OF LIPOTEICHOIC ACIDS - TOLL-LIKE RECEPTOR 2 AGONISTS | 2022 |
|
RU2781012C1 |
| RECOMBINANT PLASMID DNA pQE30/derf2L CODING PROTEIN der f 2L OF MITE Dermatophagoides farinae, AND BACTERIAL STRAIN Escherichia coli M15/pQE30/derf2L - PRODUCER OF SUCH PROTEIN | 2012 |
|
RU2522817C9 |
| AGENT FOR DIFFERENTIATION OF MONOCYTE-LIKE CELLS | 2014 |
|
RU2590696C2 |
| APPLICATION OF PHOTOTROPHIC BACTERIA RHODOBACTER CAPSULATUS PG LIPOPOLISACCHARIDE AS FACTOR AFFECTING DIFFERENTIATION ACTIVITY OF 1ALFA,25-DIHYDROXYVITAMIN D3 | 2016 |
|
RU2642309C1 |
| PHARMACEUTICAL PRODUCT CONTAINING MITE ALLERGEN EXTRACT(S) AND METHOD FOR PRODUCTION THEREOF | 2018 |
|
RU2711727C1 |
| STRAIN OF RHODOBACTER CAPSULATUS PG - PRODUCER OF LIPOPOLYSSACHARIDE, ENDOTOXIN ANTAGONIST | 2008 |
|
RU2392309C1 |
| METHOD OF ALLERGEN-SPECIFIC IMMUNOTHERAPY EFFICIENCY EVALUATION APPLIED FOR CHILDREN SUFFERING FROM BRONCHIAL ASTHMA | 2007 |
|
RU2327993C1 |
| METHOD FOR ENCAPSULATING ALLERGENS INTO CHITOSAN PARTICLES TO REDUCE RECOGNITION OF ALLERGENS BY IgE ANTIBODIES DURING ALLERGEN-SPECIFIC SUBCUTANEOUS AND TRANSEPIDERMAL IMMUNOTHERAPY | 2020 |
|
RU2760672C1 |
| PHARMACEUTICAL PRODUCT CONTAINING EXTRACT(S) OF ALLERGEN TONGS AND METHOD FOR PRODUCTION THEREOF | 2011 |
|
RU2593778C2 |
| PHARMACEUTICAL PRODUCT CONTAINING MITES ALLERGEN EXTRACT(S), AND METHOD FOR PRODUCTION THEREOF | 2011 |
|
RU2710544C2 |
